Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart Disease
Launched by JOSE SEIJAS AMIGO · May 14, 2024
Trial Information
Current as of February 08, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥18 years
- • 2. Prior diagnosis of chronic coronary disease
- At least one of the following:
- • 1. Type 2 diabetes mellitus
- • 2. Familial hypercholesterolemia
- • 3. Recurrent coronary disease
- • 4. Chronic kidney disease
- 3. Currently undergoing pharmacological treatment with high-potency statins, with or without ezetimibe. The allowed statins and daily doses are:
- • 1. Atorvastatin 80mg
- • 2. Rosuvastatin 20mg
- • 3. Rosuvastatin 40mg
- • 4. Patients on other statins or lower doses are acceptable if there has been documented intolerance to the specified molecules and doses.
- • 4. Blood analysis with a lipid profile in the last 6 months and with the current treatment showing LDL levels \>100mg/dl.
- Exclusion Criteria:
- • 1. Not receiving statins in the therapeutic regimen.
- • 2. Concomitant treatment with PCSK9 inhibitors.
- • 3. Pregnancy, breastfeeding, or a desire to conceive by the patient.
- • 4. Patients who, in the opinion of the investigator, are unable to adequately follow up in the chronic care program under routine clinical practice.
About Jose Seijas Amigo
Jose Seijas Amigo is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on rigorous scientific standards and ethical practices, the organization collaborates with healthcare professionals, researchers, and regulatory bodies to facilitate the development of new therapies and treatment modalities. By prioritizing patient safety and regulatory compliance, Jose Seijas Amigo aims to contribute significantly to the medical community and improve patient outcomes through well-designed clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ribeira, A Coruña, Spain
A Estrada, A Coruña, Spain
Ames, A Coruña, Spain
Santiago De Compostela, A Coruña, Spain
Melide, , Spain
Pontevedra, , Spain
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0